502 related articles for article (PubMed ID: 18355324)
21. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
22. Saxagliptin + metformin. Mostly disadvantages.
Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
[No Abstract] [Full Text] [Related]
23. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Cook W; Bryzinski B; Slater J; Frederich R; Allen E
Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
[TBL] [Abstract][Full Text] [Related]
24. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
26. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
27. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
DeFronzo RA; Hissa MN; Garber AJ; Luiz Gross J; Yuyan Duan R; Ravichandran S; Chen RS;
Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
[TBL] [Abstract][Full Text] [Related]
29. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson JG; Hellqvist Å; Gause-Nilsson I
Int J Clin Pract; 2013 Apr; 67(4):307-16. PubMed ID: 23638466
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
Kadowaki T; Muto S; Ouchi Y; Shimazaki R; Seino Y
Expert Opin Pharmacother; 2017 Dec; 18(18):1903-1919. PubMed ID: 28901796
[TBL] [Abstract][Full Text] [Related]
31. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Fonseca V; Zhu T; Karyekar C; Hirshberg B
Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Leiter LA; Teoh H; Braunwald E; Mosenzon O; Cahn A; Kumar KM; Smahelova A; Hirshberg B; Stahre C; Frederich R; Bonnici F; Scirica BM; Bhatt DL; Raz I;
Diabetes Care; 2015 Jun; 38(6):1145-53. PubMed ID: 25758769
[TBL] [Abstract][Full Text] [Related]
33. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
[TBL] [Abstract][Full Text] [Related]
34. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
35. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.
Leibowitz G; Cahn A; Bhatt DL; Hirshberg B; Mosenzon O; Wei C; Jermendy G; Sheu WH; Sendon JL; Im K; Braunwald E; Scirica BM; Raz I
Diabetes Obes Metab; 2015 May; 17(5):487-94. PubMed ID: 25656169
[TBL] [Abstract][Full Text] [Related]
36. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Tahrani AA; Piya MK; Barnett AH
Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
[TBL] [Abstract][Full Text] [Related]
37. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
Rosenstock J; Aguilar-Salinas C; Klein E; Nepal S; List J; Chen R;
Curr Med Res Opin; 2009 Oct; 25(10):2401-11. PubMed ID: 19650754
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
Orime K; Terauchi Y
Expert Opin Pharmacother; 2020 Dec; 21(17):2101-2114. PubMed ID: 32990096
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
[TBL] [Abstract][Full Text] [Related]
40. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
Gerrald KR; Van Scoyoc E; Wines RC; Runge T; Jonas DE
Diabetes Obes Metab; 2012 Jun; 14(6):481-92. PubMed ID: 22098472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]